Observational studyPloS one2025
Discrepancies at clinical presentation of patients with soft tissue sarcoma according to the type of health insurance in a Brazilian population.
Observational study in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Brazil, 75% of the population is covered by public health insurance (PubHIn), and the rest pay for private insurance (PrivHIn). The impact of the type of health insurance on clinical presentation of Brazilian patients diagnosed with soft tissue sarcoma (STS) is unknown. We aim to describe the clinical characteristics at diagnosis of patients with STS, stratifying them by type of health insurance, and to evaluate the symptom-diagnosis and -treatment intervals.
methodsObservational, retrospective cohort, single-center study conducted in a Brazilian cancer center that admits both private and public patients. Medical records of individuals with 18 years old or more diagnosed with selected types of STS who started treatment in our center between January 2011 and December 2019 were reviewed. Kaplan-Meier method and log-rank test were used for survival analyses. Chi-square and Mann Whitney test were used for univariate analysis. Significance was defined as a p-value <0.05.
results225 patients were included: 25.3% (n=57) with PubHIn and 74.7% (n=168) with PrivHIn. Median tumor size in PrivHIn was 7 cm (0.9-45 cm) versus 10.3 cm (0.8-30.5 cm) in PubHIn (p=0.0001). Metastases were present in 8.9% of patients with PrivHIn (n=15) and in 26.3% (n=15) of those with PubHIn (p=0.002). Median symptom-diagnosis interval was 195 days in the PubHIn group and 163 days in the PrivHIn group (p=0.74). For the whole series, median age at diagnosis was 51 years (18-85 yo). Lower limbs were the most frequent location of tumors (53.8%), and 86% had histological grade 2/3.
conclusionsPatients with STS covered by PubHIn presented larger tumors and more metastatic disease at diagnosis, suggesting that there may be disparities in health care delivery and limited access to health resources. A better understanding of the barriers in the journey of patients with STS could improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.